Gonzales, J., N. Acharya, E. Sugar, A. Burke, A. Vitale, V. Gupta, J. Dunn, S. Lightman, J. Thorne, R. Kim, S. Yeh, M. Altaweel, J. Kempen, J. Holbrook, and D. Jabs. Macular Edema Ranibizumab Versus Intravitreal Anti-Inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-Treatment. Ophthalmology, 2024, p. Epub PubMed Text.
Abstract
Purpose: Evaluation of longer-term effectiveness of 3 intravitreal therapies (methotrexate, ranibizumab, or dexamethasone implant) for participants enrolled in the randomized comparative effectiveness trial the Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy (MERIT) Trial followed up for 24 weeks.